Fresenius Kabi AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fresenius Kabi AG
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
The European Medicines Agency has delivered its verdict on the latest medicines it believes should be approved for marketing in the EU. By contrast, it has given the thumbs down to one biosimilar anticancer drug and its duplicate.
Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.
Multiple firms have launched bortezomib products for subcutaneous administration in the US, adding to competition on Takeda’s Velcade brand.
- Generic Drugs
- Infusion Therapy Equipment and Supplies